Associations among serum insulin, calprotectin, and C‐reactive protein concentrations in Miniature Schnauzers with idiopathic hyperlipidemia before and after feeding an ultra‐low‐fat diet

Xenoulis, Panagiotis G.; Heilmann, Romy M.; Stavroulaki, Evangelia M.; Riggers, Denise S.; Gneipel, Laura J; Suchodolski, Jan S.; Steiner, Jöerg M.

doi:10.1111/jvim.16418

Cited by 3 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Primary (idiopathic) HTG in Miniature Schnauzers often remains subclinical for some time, leading to a late-stage diagnosis and the risk of patients presenting with secondary conditions or complications (e.g., pancreatitis, ophthalmic signs, proteinuria, or even seizures) [ 25 , 29 , 30 ], and can be associated with a subclinical inflammatory phenotype and insulin resistance [ 31 ]. Previous studies revealed HTG to be associated with hypercalprotectinemia, a marker of systemic inflammation [ 32 , 33 , 34 ]. However, serum α 1 -proteinase inhibitor concentrations (α 1 PI, a serum antiprotease), calprotectin, and S100A12 concentrations (inflammatory markers) have not been extensively evaluated in dogs with pancreatitis.…”

Section: Introductionmentioning

confidence: 99%

Serum α1-Proteinase Inhibitor, Calprotectin, and S100A12 Concentrations in the Characterization of Pancreatitis in Dogs

Jandel,

Heilmann,

Sander

et al. 2023

Veterinary Sciences

Self Cite

View full text Add to dashboard Cite

Miniature Schnauzers are predisposed to develop pancreatitis, with familial hypertriglyceridemia (HTG) described as a potential risk factor. Diagnosing pancreatitis in dogs is based on the integration of serum canine-specific pancreatic lipase (cPLI) concentration, clinical presentation, and diagnostic imaging findings. However, markers of systemic inflammation and antiprotease activity have not been extensively investigated in the characterization and prognostication of pancreatitis in dogs. Serum concentrations of alpha1-proteinase inhibitor (α1PI; as a marker of systemic antiprotease response) and calprotectin and S100A12 (as markers of systemic inflammation) were measured in serum samples from 35 Miniature Schnauzers diagnosed with pancreatitis (serum cPLI concentration >400 μg/L, clinical signs, abdominal imaging findings). These markers were evaluated for possible associations with patient characteristics, clinical presentation, risk factors for pancreatitis, and outcome. The study showed that biomarkers of systemic inflammation and antiprotease activity are commonly increased in Miniature Schnauzers with pancreatitis. Whereas serum calprotectin and S100A12 concentrations were found to have limited utility in differentiating pancreatitis presentations, serum α1PI concentrations and potentially also the serum calprotectin-to-S100A12 ratio might be non-invasive surrogate markers of disease severity in dogs with pancreatitis.

show abstract